Novartis Venture Fund

They are stage agnostic (seed to commercial companies) and invest in multiple therapeutic areas where there is clear unmet medical need. Their first step in the process is to review non-confidential information about the company, team, technology / data, financial and exit plan. The further evaluation of business proposals is then based on confidential presentations by the management team that starts the full due diligence process.

Investments by the Novartis Venture Fund are made as equity participation typically as the lead or co-lead investor in a syndicate with a board seat.

Fund information

Investment areas

They primary focus is on the development of novel therapeutics and platforms. In Their investments They look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency in the program.

Other information

Invest Globally: They invest in North America, Europe and Israel with approximately USD 750 million under management in committed capital. They continue Their strategy of making larger focused investments and anticipate total investments up to USD 30 million per company over its life. Invest Across Healthcare Sector: They make equity investments in Biotechnology/Biopharma life sciences companies. NVF is stage agnostic and engages in seed investments as well as later-stage investments. They typically lead or co-lead an investment and play an active role on company boards.

Ways of communication
https://www.nvfund.com

For any questions, contact them at info.nvf@nvfund.com (Global inquiries) or info.us@nvfund.com (North America inquiries)